Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions β€” written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Extranodal NK-T-cell lymphoma medical therapy

Introduction

Overview

Overview

The predominant therapy for extranodal NK-T-cell lymphoma is radiation therapy. Adjudicative chemotherapy and stem cell transplant may be required.

Medical Therapy

Medical Therapy

Stage Involvement Common involvement place Preferred therapy method Radiation dosage Chemotherapy regimen Alternative therapy Over 69 /severe organ damage/low lymphocyte
I(E) Single extranodal involvement upper aerodigestive tract Combined modality therapy‑ 50 Gy RT DeVIC∞ 40 Gy RT + weekly Cisplatin –
II(E) Stage I(E) +One or more of † involvements upper aerodigestive tract Combined modality therapy 50 Gy RT DeVIC 40 Gy RT + weekly Cisplatin –
III(E)β€’ Stage I (E) + Cervical lymph node involvement + infra diaphragmatic lymph node / Involvement of spleen Systemic /

Disseminated

SMILEαŸ› – – – Less intensive L-asparaginase-containing chemotherapy
IV Stage I(E) +isolated distant involvement Systemic /

Disseminated

SMILE – – – Less intensive L-asparaginase-containing chemotherapy

†: Cervical lymph node involvement / Involvement of other supradiaphragmatic lymph node regions / Isolated involvement of additional sites in the head and neck

β€’: Rare

‑: Combined modality therapy is radiation therapy with concurrent chemotherapy

∞: Dexamethasone, Etoposide, Ifosfamide, Carboplatin.

αŸ›: Dexamethasone. Methotrexate, Ifosfamide, L-asparaginase, Etoposide

Treatment of extranodal NK-T-cell lymphoma[1]
Therapy Description
Radiation therapy
Chemotherapy
Stem cell transplant
  • May be offered to some people with extranodal NK-T-cell lymphoma who relapse after initial treatment
References

References

  1. ↑ 1.0 1.1 Extranodal NK/T-cell lymphoma, nasal type. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/extranodal-nk-t-cell-lymphoma-nasal-type/?region=on. Accessed on February 02, 2016
  2. ↑ Dreyling, M.; Thieblemont, C.; Gallamini, A.; Arcaini, L.; Campo, E.; Hermine, O.; Kluin-Nelemans, J. C.; Ladetto, M.; Le Gouill, S.; Iannitto, E.; Pileri, S.; Rodriguez, J.; Schmitz, N.; Wotherspoon, A.; Zinzani, P.; Zucca, E. (2013). “ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma”. Annals of Oncology. 24 (4): 857–877. doi:10.1093/annonc/mds643. ISSNΒ 1569-8041.
  3. ↑ Isobe, Koichi; Uno, Takashi; Tamaru, Jun-ichi; Kawakami, Hiroyuki; Ueno, Naoyuki; Wakita, Hisashi; Okada, Jun-ichi; Itami, Jun; Ito, Hisao (2006). “Extranodal natural killer/T-cell lymphoma, nasal type”. Cancer. 106 (3): 609–615. doi:10.1002/cncr.21656. ISSNΒ 0008-543X.
  4. ↑ Li, Ye-Xiong; Yao, Bo; Jin, Jing; Wang, Wei-Hu; Liu, Yue-Ping; Song, Yong-Wen; Wang, Shu-Lian; Liu, Xin-Fan; Zhou, Li-Qiang; He, Xiao-Hui; Lu, Ning; Yu, Zi-Hao (2006). “Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma”. Journal of Clinical Oncology. 24 (1): 181–189. doi:10.1200/JCO.2005.03.2573. ISSNΒ 0732-183X.
  5. ↑ Kim, Seok Jin; Yang, Deok-Hwan; Kim, Jin Seok; Kwak, Jae-Yong; Eom, Hyeon-Seok; Hong, Dae Sik; Won, Jong Ho; Lee, Jae Hoon; Yoon, Dok Hyun; Cho, Jaeho; Nam, Taek-Keun; Lee, Sang-wook; Ahn, Yong Chan; Suh, Cheolwon; Kim, Won Seog (2014). “Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study”. Annals of Hematology. 93 (11): 1895–1901. doi:10.1007/s00277-014-2137-6. ISSNΒ 0939-5555.


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]